| Revenue growth | 11% YoY for FY26. |
|---|---|
| Margins | HPMC margins guided at 18%, Gelatin at 13%. |
| Order book | 36-day backlog for all capsule types. |
| Demand visibility | Slow demand in US Neutra segment; recovery expected in 3-6 months. |
| Management confidence | Cautious; focused on restoring consolidated profitability in FY27. |
Growth
FY26 revenue ₹187.20cr vs ₹169.21cr FY25. Q4 EBITDA recovered to ₹1.33cr (2.28% margin).
Outlook
FY27 revenue guidance ₹274cr; target for USFDA approval within 24 months; ₹25-30cr capex planned for clean rooms.
Risks
Chinese overcapacity depressing API prices; regulatory delays for US market approvals; high finance costs from debt.
Earnings Call filed with BSE, NSE: NATCAPSUQ. Summary written with AI assistance from the document.
Natural Capsules Ltd: key numbers
- Share price
- ₹169.52
- Market cap
- ₹176.5 Cr
- Revenue (annual)
- ₹187.2 Cr
- Net profit (annual)
- ₹-24.66 Cr
- P/E (TTM)
- -8.2×Sector 50.4×
- Promoter holding
- 50.92%-0.12% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Natural Capsules Ltd
All →Natural Capsules Annual General Meeting
Natural Capsules Ltd dispatched a corrigendum to its upcoming EGM notice, revising the issue price and quantity for the proposed preferential allotment of shares and warrants.
Natural Capsules Fund Raise of ₹10.01 Cr
Natural Capsules Limited approved a revised preferential issue of 1,12,500 equity shares and 4,50,000 convertible warrants. The total aggregate fund raise is valued at Rs. 10.01 Crore.
- Value
- ₹10.01 Cr
Natural Capsules Investor Presentation: Key Takeaways
NCL reported Q1FY27 revenue of ₹48.71 Cr (+8% Y-o-Y) with EBITDA at ₹1.12 Cr. Strategy focuses on scaling steroidal API volumes and HPMC line conversions to optimize capacity.
Natural Capsules Q1 FY27 Results: Net Loss of ₹5.7 Cr, Loss Widens
Natural Capsules Ltd reported revenue from operations of ₹48.7 Cr (+7.7% YoY) and a net loss of ₹5.7 Cr for Q1 FY27.
- Key figure
- Net loss ₹5.7 Cr
Natural Capsules Earnings Call: Key Takeaways
Natural Capsules reports Q4FY26 revenue of ₹58.45 Cr (+30% Y-o-Y) while facing a PAT loss of ₹4.98 Cr. Strategy focuses on steroidal API scaling and HPMC capsule expansion.
Natural Capsules Q4 FY26 Results: Net Loss of ₹5 Cr
Natural Capsules Ltd reported revenue from operations of ₹58.5 Cr (+30.0% YoY) and a net loss of ₹5 Cr for Q4 FY26.
- Key figure
- Net loss ₹5 Cr